Hans J. Deeg

Oncology

1100 Fairview Ave N
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 182 publications

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.

Journal: American journal of hematology

Published: December 15, 2025

Exposure to Agent Orange and Association with Myelodysplastic Syndromes.

Exposure to Agent Orange and Association with Myelodysplastic Syndromes.

Journal: Blood advances

Published: December 01, 2025

Exposure to Agent Orange and association with myelodysplastic syndromes.

Exposure to Agent Orange and association with myelodysplastic syndromes.

Journal: Blood advances

Published: December 01, 2025

A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study.

A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study.

Journal: Blood advances

Published: October 17, 2025

A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.

A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.

Journal: Blood advances

Published: October 17, 2025

Pre-Hematopoietic Cell Transplantation Ruxolitinib in Transplantation-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study.

Pre-Hematopoietic Cell Transplantation Ruxolitinib in Transplantation-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study.

Journal: Transplantation and cellular therapy

Published: July 21, 2025

Disease Burden at the Time of Transplantation Is a Primary Predictor of Outcomes in Pediatric MDS: A Single-Center Experience.

Disease Burden at the Time of Transplantation Is a Primary Predictor of Outcomes in Pediatric MDS: A Single-Center Experience.

Journal: Cancers

Published: April 08, 2025

A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.

A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.

Journal: Future oncology (London, England)

Published: March 07, 2025

Long-term outcomes and quality of life with treosulfan-based conditioning in hematological malignancies.

Long-term outcomes and quality of life with treosulfan-based conditioning in hematological malignancies.

Journal: Blood advances

Published: November 18, 2024

Pretransplant Chromosome Genomic Array Testing Improves Prognostication for Myelofibrosis Patients Undergoing Transplantation.

Pretransplant Chromosome Genomic Array Testing Improves Prognostication for Myelofibrosis Patients Undergoing Transplantation.

Journal: Transplantation and cellular therapy

Published: October 22, 2024

Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study.

Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study.

Journal: EClinicalMedicine

Published: May 13, 2024

Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study.

Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study.

Journal: Blood neoplasia

Published: March 26, 2024

Showing 1-12 of 182

Last Updated: 09/26/2026